Cancer Therapy

Data provide rationale for KOS-862 combination clinical trials

Published in Cancer Weekly, April 27th, 2004

Kosan Biosciences (KOSN) announced at the 95th annual meeting of the American Association for Cancer Research in Orlando, Florida, preclinical in vivo and in vitro data on the cytotoxic and antiproliferative effects of combining Kosan's lead epothilone, KOS-862 (Epothilone D) with two different standard chemotherapies.

Data from these preclinical studies led to the conclusion that the clinical investigation of KOS-862 in combination with carboplatin (Paraplatin) or capecitabine (Xeloda) should be considered.

In the study investigating KOS-862 and carboplatin ("KOS-862 (Epothilone D) and Carboplatin Demonstrate In Vitro and In Vivo Synergy Against...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-04-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry